Layoffs hit Raleigh pharma company amid shakeup
SAGE Stock | USD 7.19 0.02 0.28% |
About 63% of all Sage Therapeutic's shareholders are looking to take a long position. The analysis of the overall investor sentiment regarding Sage Therapeutic suggests that some traders are interested. The current market sentiment, together with Sage Therapeutic's historical and current headlines, can help investors time the market. In addition, many technical investors use Sage Therapeutic stock news signals to limit their universe of possible portfolio assets.
Sage |
More layoffs are hitting the pharmaceutical sector in the Raleigh area.
Read at bizjournals.com
![]() |
Sage Therapeutic Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Sage Therapeutic can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Sage Therapeutic Fundamental Analysis
We analyze Sage Therapeutic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Sage Therapeutic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Sage Therapeutic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Income
Net Income Comparative Analysis
Sage Therapeutic is currently under evaluation in net income category among its peers. Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Sage Therapeutic Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Sage Therapeutic stock to make a market-neutral strategy. Peer analysis of Sage Therapeutic could also be used in its relative valuation, which is a method of valuing Sage Therapeutic by comparing valuation metrics with similar companies.
Peers
Sage Therapeutic Related Equities
VTYX | Ventyx Biosciences | 8.97 | ||||
BPMC | Blueprint Medicines | 6.80 | ||||
PLRX | Pliant Therapeutics | 5.52 | ||||
ALNY | Alnylam Pharmaceuticals | 4.07 | ||||
AMLX | Amylyx Pharmaceuticals | 3.80 | ||||
BDTX | Black Diamond | 3.61 | ||||
KRYS | Krystal Biotech | 3.40 | ||||
ARVN | Arvinas | 2.55 | ||||
DMAC | DiaMedica Therapeutics | 2.35 | ||||
MDGL | Madrigal Pharmaceuticals | 1.65 | ||||
INCY | Incyte | 0.44 | ||||
AKRO | Akero Therapeutics | 0.34 | ||||
NUVL | Nuvalent | 0.09 | ||||
IMCR | Immunocore Holdings | 0.71 | ||||
STOK | Stoke Therapeutics | 1.75 | ||||
TERN | Terns Pharmaceuticals | 1.86 | ||||
APLS | Apellis Pharmaceuticals | 3.27 | ||||
DAWN | Day One | 4.03 | ||||
RLAY | Relay Therapeutics | 13.33 |
Complementary Tools for Sage Stock analysis
When running Sage Therapeutic's price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Stocks Directory Find actively traded stocks across global markets | |
My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |